Loading...
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
Ertugliflozin, an inhibitor of sodium‐glucose cotransporter 2, is approved in the United States and European Union for the treatment of type 2 diabetes in adults, both as monotherapy and as part of fixed‐dose combination (FDC) therapies with either sitagliptin or immediate‐release metformin. The eff...
Saved in:
| Published in: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6618047/ https://ncbi.nlm.nih.gov/pubmed/30427588 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.629 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|